Century Therapeutics (NASDAQ:IPSC) Announces Quarterly Earnings Results

Century Therapeutics (NASDAQ:IPSC – Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.01, FiscalAI reports.

Century Therapeutics Trading Down 6.3%

IPSC stock traded down $0.11 during trading hours on Thursday, hitting $1.63. 608,756 shares of the stock traded hands, compared to its average volume of 1,004,740. The stock has a 50-day simple moving average of $1.65 and a 200 day simple moving average of $2.07. The company has a market cap of $295.14 million, a P/E ratio of -1.75 and a beta of 1.78. Century Therapeutics has a one year low of $0.43 and a one year high of $3.04.

Analyst Ratings Changes

Several research analysts have recently issued reports on IPSC shares. Wall Street Zen cut shares of Century Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, October 31st. Weiss Ratings reissued a “sell (d-)” rating on shares of Century Therapeutics in a report on Tuesday, September 29th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $4.75.

Get Our Latest Analysis on Century Therapeutics

About Century Therapeutics

(Get Free Report)

Century Therapeutics is a biotechnology company developing cell-based therapies for cancer and other serious diseases. Its research focuses on allogeneic treatments, which are designed to be produced from donor cells rather than made separately for each patient. The company uses induced pluripotent stem cell technology to create immune cells, including natural killer cells and T cells, that can be engineered to recognize and attack disease. Its work includes developing cell therapies with genetic modifications intended to improve their activity and persistence.

Read More

Earnings History for Century Therapeutics (NASDAQ:IPSC)

Receive News & Ratings for Century Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Century Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.